Tarsus Pharmaceuticals, Inc.
TARS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,082 | $595 | $361 | $462 |
| - Cash | $95 | $225 | $72 | $171 |
| + Debt | $72 | $32 | $20 | $2 |
| Enterprise Value | $2,060 | $402 | $309 | $293 |
| Revenue | $183 | $17 | $26 | $57 |
| % Growth | 948.6% | -32.4% | -54.7% | – |
| Gross Profit | $170 | $16 | $25 | $55 |
| % Margin | 93% | 90.9% | 96.3% | 96.4% |
| EBITDA | -$106 | -$132 | -$60 | -$13 |
| % Margin | -58.2% | -754.7% | -231.3% | -23.6% |
| Net Income | -$116 | -$136 | -$62 | -$14 |
| % Margin | -63.2% | -778.9% | -240.5% | -24.2% |
| EPS Diluted | -3.07 | -4.62 | -2.52 | -0.67 |
| % Growth | 33.5% | -83.3% | -276.1% | – |
| Operating Cash Flow | -$83 | -$117 | -$49 | $4 |
| Capital Expenditures | -$2 | -$6 | -$1 | -$1 |
| Free Cash Flow | -$85 | -$123 | -$50 | $3 |